Cat. No. | Product name | CAS No. |
DC9394 |
LDC000067
Featured
LDC000067(LDC-067) is a highly specific CDK9 inhibitor with IC50 of 32.7 nM for CDK9/cyclin T1; displays 55/125/210/ >227/ >227-fold selectivity for CDK9 versus CDK2/1/4/6/7. |
1073485-20-7 |
DC10143 |
LDC-4297
Featured
LDC4297 is a novel CDK7 inhibitor. |
1453834-21-3 |
DC9773 |
LEE011 hydrochloride
Featured
LEE011 Hcl is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
1211443-80-9 |
DC7453 |
Ribociclib (LEE011)
Featured
LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
1211441-98-3 |
DC9774 |
LEE011 succinate
Featured
LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
1374639-75-4 |
DC8643 |
LY2835219 free base (Abemaciclib)
Featured
LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
1231929-97-7 |
DC5062 |
LY2835219(Abemaciclib)
Featured
LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
1231930-82-7 |
DC9766 |
LY3177833
Featured
LY3177833 is a novel CDC7 inhibitor,CDC7/DBF4 IC50 = 3.3 nM, pMCM2 (S53) IC50 = 290 nM and IVTI TEC70 = 1.6 mcM. |
1627696-51-8 |
DC9741 |
Mad2 inhibitor-1 (M2I-1)
Featured
Mad2 Inhibitor-1 (M2I-1) is a small molecule protein-protein interaction inhibitor targeting the mitotic spindle assembly checkpoint. |
312271-03-7 |
DC10627 |
MSC2530818
Featured
MSC2530818, a CDK8 inhibitor with the IC50 of 2.6 nM, displays excellent kinase selectivity, biochemical and cellular potency, microsomal stability, and is orally bioavailable. |
1883423-59-3 |
DC9988 |
NSC23005 sodium
Featured
NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models. |
1796596-46-7 |
DC8214 |
NU6027
Featured
NU 6027 inhibits both CDK1 and CDK2 with IC50 values of 2.9 and 2.2 µM, respectively. |
220036-08-8 |
DC10734 |
NU2058
Featured
NU2058 is a guanine-based CDK inhibitor with IC50 of 17 μM and 26 μM for CDK2 and CDK1. |
161058-83-9 |
DC8716 |
NU6300
NU6300 is a non-covalent ATP-competitive CDK2 inhibitor (IC50 = 0.16 mM). |
|
DC9392 |
NVP-LCQ195
Featured
NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM. |
902156-99-4 |
DC9253 |
ON123300
Featured
ON123300 is a novel multiple kinase inhibitor. |
1357470-29-1 |
DC8469 |
Palbociclib
Featured
Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. |
571190-30-2 |
DC5067 |
Palbociclib (PD0332991 HCl)
Featured
Palbociclib is an oral, small molecule cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, now in Phase 3 clinical development for advanced breast cancer. |
827022-32-2 |
DC8470 |
Palbociclib isethionate
Featured
Palbociclib isethionate(PD-0332991 isethionate) is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. |
827022-33-3 |
DC9391 |
PHA-767491 (hydrochloride)
PHA-767491 (CAY10572) Hcl is a potent, ATP-competitive dual Cdc7/Cdk9 inhibitor with IC50 values of 10/34 nM. |
942425-68-5 |
DC8025 |
CAY10572(PHA-767491)
Featured
PHA-767491 (CAY10572) is a potent, ATP-competitive dual Cdc7/Cdk9 inhibitor with IC50 values of 10/34 nM. |
845714-00-3 |
DC4123 |
PHA-793887
Featured
PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM, respectively. |
718630-59-2 |